Overview

Join Dr Sophia Ambruso (University of Colorado, Denver, US) and Prof Paolo Mulatero (University of Turin, Turin, IT) for Part 2 of 'Spotlight on Uncontrolled Hypertension: Assessing the Shift Towards Personalised Medicine'. Together they will discuss how real-world evidence is reshaping the management of uncontrolled hypertension (HTN). 

They will bring their real-world insights on aldosterone dysregulation and aggressive blood pressure lowering, including findings from the STEP trial. Looking ahead, we’ll examine emerging therapeutic targets, the limitations of mineralocorticoid receptor antagonists (MRAs), and novel approaches like nonsteroidal MRAs, endothelin receptor antagonists and angiotensinogen inhibition. Special focus will be given to aldosterone synthase inhibitors (ASIs), their mechanism of action and clinical data.